(MedPage Today) — NEW ORLEANS — Factor XIa (FXIa) inhibition for secondary stroke prevention got a major win in the large OCEANIC-STROKE placebo-controlled trial.
Among adults with acute non-cardioembolic ischemic stroke or high-risk transient…
Source link : https://www.medpagetoday.com/meetingcoverage/isc/119756
Author :
Publish date : 2026-02-05 20:19:00
Copyright for syndicated content belongs to the linked Source.
